Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

Survival outcomes favored the higher dose: more than 93% of patients in the 70 Gy group were alive one year after treatment, ...

Dr. Jared Weiss details the importance of continued research into novel therapies for patients with lung cancer.

The trial enrolled patients with NSCLC that had PD-L1 expression on 25% or more cells whose tumours had been completely removed with surgery. Imfinzi is already approved for unresectable ...

It sounds too simple to be true. Exercise works just as effectively as a drug to slash the risk of dying from bowel cancer, ...

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

The SMC has also has accepted Cladribine, also known as Mavenclad, for the treatment of relapsing-remitting multiple ...

Imfinzi was eventually approved for that indication by the FDA, despite the reservations. In NIAGARA, patients treated with the Imfinzi perioperative regimen showed a 32% reduction in the risk of ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted ...

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is undergoing a significant transformation in ...